Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Thu, 04.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Ladenburg, Germany, 4 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Thu, 10.07.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data
Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started
First patient in clinical study dosed with the second ATAC c [ … ]
Tue, 27.05.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Ladenburg, Germany, 27 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the first patient has been [ … ]
Thu, 15.05.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
All agenda items approved by a large majority
2025 Annual General Meeting elects Dr Karl Benedikt Biesinger and Dr Klaus Schollmeier as new members of the Supervisory Board
Supervisory Board elects Dr Karl Benedikt Biesin [ … ]
Wed, 14.05.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
HDP-101 demonstrated complete response in one female patient from cohort 5
R&D Webinar to be hosted on 17 June 2025
Ladenburg, Germany, 14 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developi [ … ]
Thu, 24.04.2025
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated
Cohort 8 expected to start soon
Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started
Amendment of contract with [ … ]
Wed, 26.03.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and [ … ]
Fri, 21.03.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Promising data from clinical trial with HDP-101 in multiple myeloma, including a complete remission in one female patient; study is making good progress
Received first approvals for the clinical study with ATAC candidate HDP-102; st [ … ]
Thu, 13.03.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
HealthCare Royalty and Heidelberg Pharma amend royalty financing agreement to provide for USD 20 million payment
Heidelberg Pharma extends cash runway into 2027
Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company [ … ]
Mon, 13.01.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
HDP-101 is well tolerated to date, with no signs of dose-limiting toxicities
Complete remission observed in one patient from Cohort 5
Proprietary novel payload with a unique mode of action, representing new [ … ]
